8-K 1 b74799oie8vk.htm OXIGENE, INC. FORM 8-K e8vk
Table of Contents

 
 
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 25, 2009
OXiGENE, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   0-21990   13-3679168
(State or other   (Commission File   (I.R.S. Employer
jurisdiction of   Number)   Identification No.)
incorporation)        
230 Third Avenue, Waltham, MA 02451
(Address of principal executive offices)
Registrant’s telephone number, including area code: (781) 547-5900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
o   Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
SIGNATURE

Table of Contents

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(a), (c) — (f) Not applicable.
(b) On March 16, 2009, Joel-Tomas Citron, Chairman of the Board of Directors of OXiGENE, Inc. (the “Company”), and Per-Olof Söderberg, a Director of the Company, notified the Company that they do not plan to stand for re-election to the Company’s Board of Directors at the 2009 annual meeting of stockholders. The Company notes its appreciation of Mr. Citron’s and Mr. Söderberg’s service on its Board of Directors.
          Effective as of the 2009 annual meeting, the employment agreement between the Company and Mr. Citron will terminate as Mr. Citron will cease to be a Director of the Company.

 

Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: March 25, 2009
  OXiGENE, Inc.    
 
        
 
  /s/ James B. Murphy    
 
       
 
  By: James B. Murphy    
 
  Vice President and Chief Financial Officer